Lexaria has developed and commercialized a patented and cost-effective delivery technology (DehydraTECH™) that has been both laboratory and market proven to enhance the performance of beneficial compounds in ingestible products across four categories:

  • Taste
  • Smell
  • Speed of action
  • Bioabsorption & bioavailability

Lexaria’s technology is easily applied through incorporation of an intermediate step in the formulation and manufacturing of existing or new ingestible products.  This step involves mixing the beneficial compound of interest as a delivery “payload” together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to conjugate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into production.

Click on the video above to view a video explaining Lexaria’s DehydraTECH™ technology and illustrating how it is used to formulate and manufacture high performance ingestible consumer products.

A Versatile Solution to Improve Bioabsorption, Taste, and Efficacy

Compounds processed using Lexaria’s DehydraTECH™ system become masked to oral and olfactory receptors, rendering them essentially flavorless and odorless.  As such, DehydraTECH™ formulations do not require unwanted sweeteners or chemical masking agents for flavor and odor blocking.  This allows manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners.

After being swallowed, the fatty acids are believed to protect the conjugated payload from hostile stomach conditions and expedite its transit to the small intestine where nutrient bioabsorption occurs.  Once in the small intestine, the fatty acids are believed to enable rapid and more significant permeation of the intestinal wall for the conjugated payload, then transport it to the systemic circulation by one of two pathways depending on the type of fatty acid(s) chosen for each specific formulation:

1. Hepatic Transport

In cases where liver metabolism is desirable for biotransformation of the payload before access to the general circulation, Lexaria’s methodology uses medium chain fatty acids for formulation purposes since they are absorbed via the portal vein and transported to the liver for processing prior to entering the general circulation.  This would be applicable, for instance, with prodrug compounds that rely on metabolism by liver enzymes to become pharmacologically active within the human body.

2. Lymphatic Transport

Conversely, in cases where faster onset of action and/or maximizing action of the originally formulated payload without biotransformation is desirable, Lexaria’s methodology uses long chain fatty acids, which are absorbed via the lymphatic lacteals thereby diverting away from the liver and entering the general circulation very quickly.  For payloads that deliver pain relief or meet other immediate needs, this rapidity of onset is a vital benefit.

DehydraTECH™ formulations may also permit formulation with a combination of long and medium chain fatty acids in the same preparation for purposes of engineering products with both fast and sustained release profiles. Such timed-release formulations can be sought to deliver beneficial payloads both quickly, as well as over a sustained duration for several hours.

DehydraTECH™ formulations have been shown through in vitro and in vivo studies to increase intestinal bioabsorption of bioactive compounds by as much as 5-10X and demonstrate effectiveness in as little as 15 minutes after administration (see:  Research).  Lexaria’s DehydraTECH™ process has the added benefit of being very cost-effective to implement; requiring micro quantities of fatty acid ingredient incorporation into food, beverage, and capsule products at a fraction of a penny per serving, together with the use of processing equipment that is readily found in most commercial kitchen/production facilities and is highly scalable.

Commercial Applications

Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) payloads.  It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:

medical cannabinoid research Laxaria Bioscience Technology | Biotechnology Engineering | Cannabinoids


The most common source of cannabinoids used in commercial products today is cannabis, through both the marijuana and hemp plant varieties. Upwards of a hundred different cannabinoid compounds have been isolated from cannabis, including those that are most well-known, like tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabinoids act upon a variety of receptors and systems in the human body to relieve pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s DehydraTECH™ technology is designed to deliver cannabinoids in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices.

medical cannabinoid research Laxaria Bioscience Technology | Biotechnology Engineering | Vitamins


Vitamins can be broken down into two broad categories; those that are water soluble and those that are fat soluble. The latter class of vitamins, including vitamins A, D, K and E, are generally harder to absorb in the intestines and, therefore, food and supplement manufacturers often use synthetic versions and/or other variants of the natural food-derived forms of these vitamins in order to make them more bioavailable. Lexaria’s DehydraTECH™ technology offers an alternate means to formulate and integrate fat soluble vitamins into oral ingestible products of virtually any type with the potential for greater overall delivery performance.

medical cannabinoid research Laxaria Bioscience Technology | Biotechnology Engineering | NSAIDs

Non-steroidal anti-inflammatory agents (NSAIDs)

NSAIDs are the second-largest category of pain management treatment options in the world. Opioids (e.g. morphine) represent the largest single pain management sector but are known to be associated with serious dependence and tolerance issues and are also the leading cause of drug death, through abuse and overuse. Some of the most commonly known NSAIDs are acetylsalicylic acid (ASA) and ibuprofen. Although NSAIDs are generally a safe and effective treatment method for pain, they have been associated with a number of gastrointestinal problems including dyspepsia and gastric bleeding. This is, in part, due to the fact that they undergo significant liver biotransformation into inactive metabolites after ingestion, thereby making it necessary to formulate NSAID consumer goods with relatively high quantities of active substance in order to offset bioavailability losses from liver processing. Lexaria’s DehydraTECH™ technology offers an alternate means to formulate oral NSAID products with lower active substance input requirements and higher bioavailability performance possibilities due to the liver bypassing effects it is believed to enable. As well, greater effectiveness at pain killing through higher bioavailability could conceivably lead to a partial offset to some current opioid use.

medical cannabinoid research Laxaria Bioscience Technology | Biotechnology Engineering | Nicotine


More than 99% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As high as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH™ technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria DehydraTECH™ technology offers a means to formulate ingestible product formats of nicotine and/or its analogues with higher bioavailability performance possibilities due to the benefits of our technology.

Lexaria’s methodology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets, capsules and more. This is accomplished through choosing an appropriate substrate compound for infusion during performance of the Lexaria formulation and manufacturing process, which can range from a foodstuff like cocoa powder or tapioca starch used in many confectionary products, or an emulsifier like gum arabic used in many beverage products. Many of the most common base ingredients used in modern processing of foods, beverages and supplements are effective to use with DehydraTECH™.


Lexaria’s DehydraTECH

Interview with CEO Chris Bunka of Lexaria BioScience

Improving the Delivery for Medical Cannabinoids – Lexaria Biosciences

Improving the Delivery for Medical Cannabinoids – Lexaria Biosciences


The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness.  Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.

Patent Portfolio

Lexaria’s DehydraTECH™ technology is covered by issued and pending patents in over 40 countries around the world.  Lexaria`s patent suite commenced with two initial 2014 US provisional patent application, which Lexaria acquired by way of exclusive, worldwide license rights and controlling interest in the founding company that made these filings.  Since then, Lexaria has broadened the patent suite considerably by refining the patent claims via further US provisional and utility patent filings and extending the breadth of the claims considerably to name many other beneficial compounds that the technology can be applied to and many other consumer product formats in which they can be formulated.  Under US patent law, a patent upon issuance provides for 20 years of patent protection from the date of filing.


In addition to the US patent filings, Lexaria has also pursued international patent protection through filings under the Patent Cooperation Treaty, followed by national filings in 40+ jurisdictions of highest commercial potential thereunder.

Consumer Products

Lexaria has three distinct consumer product brands: ViPovaTM, Lexaria Energy Foods and TurboCBD™.  All of these brands are powered by Lexaria’s patented DehydraTECH™ technology to infuse full spectrum hemp oil ingredients within lipids in popular foods and consumer products. For more information, please see: